Thomson Abigail L, Berent Allyson C, Weisse Chick, Langston Catherine E
The Animal Medical Center, Interventional Radiology and Endoscopy, New York, NY.
J Vet Intern Med. 2019 May;33(3):1353-1361. doi: 10.1111/jvim.15486. Epub 2019 Mar 29.
There are no known treatments that halt or reverse chronic kidney disease (CKD) in cats. In rodent models, stem cell treatment has been associated with improvement in renal function parameters, especially when stem cells were delivered intra-arterially to the kidney. To date, only IV and intrarenal stem cell infusions have been studied in cats with CKD with no clinically relevant improvement noted.
To assess the safety and feasibility of intra-arterial delivery of autologous mesenchymal stem cells (MSC) in stromal vascular fraction (SVF) to the kidney in cats with CKD.
Five client-owned domestic cats with International Renal Interest Society stage III CKD.
Prospective cohort study (phase I clinical trial). Adipose tissue was harvested from study animals on day 0. On days 2 and 14, an infusion of MSC in SVF was administered into the renal artery via the femoral or carotid artery using fluoroscopic guidance. Serum creatinine and blood urea nitrogen concentration, plasma iohexol clearance, and quality of life assessments were monitored between days 0 and 90.
The procedure was performed successfully in all cats. No severe adverse events were observed in any cat during the study period.
Intra-arterial infusion of MSC into the renal artery in CKD cats was feasible and safe within a 3-month postoperative period. Efficacy and long-term safety have yet to be established. This procedure requires careful technique and training.
目前尚无已知的治疗方法能阻止或逆转猫的慢性肾病（CKD）。在啮齿动物模型中，干细胞治疗与肾功能参数的改善有关，尤其是当干细胞通过动脉内注射到肾脏时。迄今为止，在患有CKD的猫中仅研究了静脉内和肾内干细胞输注，未观察到临床相关的改善。
评估将自体间充质干细胞（MSC）在基质血管成分（SVF）中经动脉注射到患有CKD的猫的肾脏中的安全性和可行性。
5只客户拥有的患有国际肾脏兴趣协会III期CKD的家养猫。
前瞻性队列研究（I期临床试验）。在第0天从研究动物身上采集脂肪组织。在第2天和第14天，在荧光透视引导下，通过股动脉或颈动脉将SVF中的MSC输注到肾动脉中。在第0天至90天期间监测血清肌酐和血尿素氮浓度、血浆碘海醇清除率以及生活质量评估。
所有猫均成功完成该操作。在研究期间，任何猫均未观察到严重不良事件。
在术后3个月内，将MSC经动脉输注到患有CKD的猫的肾动脉中是可行且安全的。疗效和长期安全性尚未确立。该操作需要仔细的技术和培训。
